CV with publications 150525

Curriculum Vitae
Publications
Mattias Collin
May 2015
PERSONAL INFORMATION
Collin, Mattias
Born Oct 12, 1971
tinyurl.com/thecollinlab
Researcher ID: C-6398-2009 Google Scholar: Mattias Collin
EDUCATION
2001
PhD in Cell and Molecular Biology with the thesis "Streptococcus pyogenes secreted
enzymes interacting with the human host", Department of Cell and Molecular Biology,
Faculty of Medicine, Lund University, Sweden. Supervisor: Dr Arne Olsén.
1996
Four years of Medical School plus a 1.5 semester thesis (eq. to Masters), Lund
University, Sweden.
CURRENT POSITIONS
2015
Senior Lecturer (tenured) in Infection Medicine, Lund University, Sweden
2009 –
Associate Professor in Experimental Infection Medicine, Lund University, Sweden.
PREVIOUS POSITIONS
2012 –
Research Fellow (tenured) in Infection Medicine, Lund University, Sweden.
2011 – 2012 Non-tenure Senior Lecturer and Research Fellow, Infection Medicine, Lund
University, Sweden.
2006 – 2011
Assistant Professor in Experimental Infection Research, Lund University, Sweden.
2005 – 2005 Postdoctoral Fellow at Clinical and Experimental Infection Medicine, Lund
University
2001 – 2004 Postdoctoral Associate at the Rockefeller University, New York, USA.
FELLOWSHIPS AND AWARDS
2001 – 2003
Postdoctoral Fellowship from the Wenner-Gren Foundations.
2004 – 2005
Postdoctoral Fellowship from the Swedish Society for Medical Research.
2006 – 2011
Assistant Professorship from the Swedish Research Council (4 years).
2009
The Swedish Society for Medicine's prize (1/y) for best project (100,000 SEK).
2010
Florman's prize (1/y) from the Swedish Royal Academy of Sciences (25,000
SEK).
2012 – 2014
Åke Wiberg Foundation’s “Million grant” scholar (1/y).
SUPERVISION OF GRADUATE STUDENTS AND POSTDOCTORAL FELLOWS
2005 – 2015
6 Postdocs (M Yadav, H Linge, J Garbe, M Allhorn, M Roupé, A Nägeli) / 3
finished PhDs (R Lood, M Bober, J Sjögren) and 3 ongoing (S Karlsson Söbirk, A Shadnezhad, E
Bratanis) as main supervisor / 5 PhD students as assisting supervisor / 9 Masters or MD
Students as main supervisor.
TEACHING ACTIVITIES AT LUND UNIVERSITY
2008 – 2015 30-50% teaching within the Biomedical Bachelors and Masters programmes, and
the Medical Program (MD). Pedagogic duties have included group mentoring,
lecturing, course leadership, examination, course development, program
leadership, and program development.
INSTITUTIONAL RESPONSIBILITIES AT LUND UNIVERSITY
2011 – 2013 Chair, Examination committee for the Biomedical program.
2009 – 2012 Member of the steering committee and webmaster for the Research program
"Chronic
Inflammation Program" (ChIP) at the Medical Faculty
(www.med.lu.se/chip).
2012–2014
Member of the steering committee, webmaster, and meeting organizer for the
Research program HOPE at the Medical Faculty (http://www.med.lu.se/hope).
2011 –
Deputy Program Director for the Biomedical Programs.
Curriculum Vitae
Publications
2013-
Mattias Collin
May 2015
Chair, Study Social Committee for the Biomedical Programs.
ORGANISATION OF SCIENTIFIC MEETINGS
2009 - 2012
Co-organization of 10 mini symposia within ChIP with local and international
speakers. Main organizer for Antibody-mediated autoimmunity - mechanisms
and future therapies, March 10, 2010, and Inflammation in the central nervous
system - mechanisms, models and clinical perspectives, October 19, 2010.
COMMISSIONS OF TRUST
2012 – 2013 Scientific Advisory Board member for the project “High-throughput Technology
for
Assessing Antibody Effector Function” within the “The Collaboration for AIDS
Vaccine Discovery (CAVD)” funded by the Bill & Melinda Gates Foundation.
2010 – 2013 Grant reviewer for National Foundation for Science, Higher Education
and
Technological Development of the Republic of Croatia (NZZ); The India Alliance The Wellcome Trust, UK and the Government of India; The Netherlands
Organization for Health Research and Development (ZonMw); and Biotechnology
and Biological Sciences Research Council (part of Research Councils UK).
2010 –
Reviewer for 2 Assistant Professorships, Karolinska Institute and Umeå
University.
2009 – 2014 Member of 9 PhD evaluation committees within the Medical and Science Faculty at
Lund University, and the Odontological Faculty at Malmö University.
2004 – 2014
Refereeing for BMC Microbiology, Cellular Microbiology, Clinical and
Experimental Immunology, Contributions to Microbiology, FEMS Microbiology Letters, Frontiers in
Microbiology, Frontiers in Public Health, Immunology Letters, Infection and Immunity, Journal of
Bacteriology, Journal of Biological Chemistry, Journal of Dental Research, Journal of Infectious
Diseases, Journal of Innate Immunity, Journal of Proteomics, mBio, Microbial
Pathogenesis, Microbiology, Molecular Immunology, Molecular Microbiology, PLoS One, PloS
Pathogens, Structure, Trends in Microbiology, Biochemistry.
2012 –
Editorial board member for Frontiers in Microbiology/Medicine/Public Health.
SELECTED MEMBERSHIPS OF SCIENTIFIC SOCIETIES
American Society for Microbiology (1996-), The Swedish Society for Medicine (1998-), The New
York Academy of Science (2008-), Society for Glycobiology (2008-), Faculty of 1000 (associate
faculty member since 2011, faculty member since 2013).
MAJOR COLLABORATIONS
Rikard Holmdahl and Kutty Selva Nandakumar, Arthritis models, Karolinska Institute, Sweden.
Falk Nimmerjahn, Fc-receptors and autoimmunity. University of Erlangen-Nürnberg, Germany.
Enno Schmidt and Ralf Ludwig, Autoimmunity of the skin, University of Lübeck, Germany.
Pauline Rudd, Advanced glycan analysis. University College Dublin, Ireland.
Weston Struwe and Max Crispin, Antibody glycosylation, Oxford University, United Kingdom.
Anders Bengtsson and Christian Lood, SLE patients and models, Lund University, Sweden.
Shozo Izui, Autoimmunity of the blood, University of Geneva, Switzerland.
Paul Bates, Parasitology, Lancaster University, United Kingdom.
PUBLICATIONS
45 original peer-reviewed articles, 7 invited reviews, 1 book edited, 1 book chapter, 4 popular science
articles, 7 patents, H-index 21/19 (with/without self citations according to Scopus).
Original peer-reviewed articles (reverse chronological order)
1.
Schulze FS, Beckmann T, Nimmerjahn F, Ishiko A, Collin M, Köhl J, Goletz S, Zillikens D, Ludwig R,
and Schmidt E: FcɣRIIB, FcɣRIII, and FcɣRIV mediate tissue destruction in experimental bullous
Curriculum Vitae
Publications
2.
3.
4.
5.
6.
7.
8.
9.
10.
11.
12.
13.
14.
15.
16.
17.
18.
19.
Mattias Collin
May 2015
pemphigoid. American Journal of Pathology 2014; 184(8), 2185-2196.
Garbe, J., Sjögren, J., Cosgrave, E. F. J., Struwe, W. B., Bober, M., Olin, A. I., Rudd, P.M., Collin, M:
EndoE from Enterococcus faecalis hydrolyzes the glycans of the biofilm inhibiting protein lactoferrin
and mediates growth. PLoS ONE 2014; 9(3), e91035.
Yu, X., Zheng, J., Collin, M., Schmidt, E., Zillikens, D., & Petersen, F. EndoS reduces the pathogenicity
of anti-mCOL7 IgG through reduced binding of immune complexes to neutrophils. PLoS ONE 2014; 9(2),
e85317.
Sjögren J, Struwe WB, Cosgrave EFJ, Rudd PM, Stervander M, Allhorn M, Hollands A, Nizet V, Collin
M: EndoS2 is a unique and conserved enzyme of serotype M49 group A Streptococcus that hydrolyses
N-linked glycans on IgG and α1-acid glycoprotein. Biochemical Journal 2013, 455:107–118.
Söbirk SK, Mörgelin M, Egesten A, Bates P, Shannon O, Collin M: Human chemokines as antimicrobial
peptides with direct parasiticidal effect on Leishmania mexicana in vitro. PLoS ONE 2013, 8:e58129.
Olivares N, Marquina B, Mata-Espinoza D, Zatarain-Barron ZL, Pinzon CE, Estrada I, Collin M, Rook
GA, Hernandez-Pando R: The protective effect of immunoglobulin in murine tuberculosis is dependent
on IgG glycosylation. Pathogens and Disease 2013; 69(3), 176–183.
Mahdia Benkchoucha, Nicolas Molnarfi, Marie-Laure Santiago-Raber, Martin S Weber, Doron Merkler,
Mattias Collin and Patrice H Lalive. IgG glycan hydrolysis by EndoS inhibits experimental autoimmune
encephalomyelitis. Journal of Neuroinflammation. 2012;9:209.
Eliasson M, Olin AI, Malmström JA, Mörgelin M, Bodelsson M, Collin M, Egesten A: Characterization
of released polypeptides during an interferon-γ-dependent antibacterial response in airway epithelial cells.
Journal of Interferon and Cytokine Research2012, 32:524–533.
Hirose M, Vafia K, Kalies K, Groth S, Westermann J, Zillikens D, Ludwig RJ, Collin M, Schmidt E:
Enzymatic autoantibody glycan hydrolysis alleviates autoimmunity against type VII collagen. Journal of
Autoimmunity. 2012; 39:304-314.
Oefner CM, Winkler A, Hess C, Lorenz AK, Holecska V, Huxdorf M, Schommartz T, Petzold D,
Bitterling J, Schoen A-L, Stoehr AD, Van DV, Darcan-Nikolaisen Y, Blanchard V, Schmudde I,
Laumonnier Y, Strover HA, Hegazy AN, Eiglmeier S, Schoen CT, Mertes MMM, Loddenkemper C,
Lohning M, Konig P, Petersen A, Luger EO, Collin M, Köhl J, Hutloff A, Hamelmann E, Berger M,
Wardemann H, Ehlers M: Tolerance induction with T cell-dependent protein antigens induces regulatory
sialylated IgGs. Journal of Allergy and Clinical Immunology 2012; 129:1647-1655.
Christian Lood, Allhorn M, Lood R, Gullstrand B, Olin A, Rönnblom L, Gunnar Sturfelt G, Truedsson L,
Collin M and Bengtsson A.A. IgG glycan hydrolysis by EndoS diminishes the pro-inflammatory
properties of immune complexes from patients with SLE – a possible new treatment? Arthritis and
Rheumatism. 2012; 64: 2698–2706.
Lood R, Collin M. Characterization and genome sequencing of two Propionibacterium acnes phages
displaying pseudolysogeny. BMC Genomics. 2011;12:198.
Bober M, Mörgelin M, Olin AI, Pawel-Rammingen von U, Collin M. The membrane bound LRR
lipoprotein Slr, and the cell wall-anchored M1 protein from Streptococcus pyogenes both interact with
type I collagen. PLoS ONE. 2011;6:e20345.
Frick I-M, Shannon O, Åkesson P, Mörgelin M, Collin M, Schmidtchen A, et al. Antibacterial activity of
the contact and complement systems is blocked by SIC, a protein secreted by Streptococcus pyogenes.
Journal of Biological Chemistry. 2011;286:1331–1340.
Sjögren J, Okumura CYM, Collin M, Nizet V, Hollands A. Study of the IgG endoglycosidase EndoS in
group A streptococcal phagocyte resistance and virulence. BMC Microbiology. 2011;11:120.
Bober M, Enochsson C, Collin M, Mörgelin M. Collagen VI is a subepithelial adhesive target for human
respiratory tract pathogens. Journal of Innate Immunity. 2010;2:160–166.
van Timmeren MM, van der Veen BS, Stegeman CA, Petersen AH, Hellmark T, Collin M, et al. IgG
glycan hydrolysis attenuates ANCA-mediated glomerulonephritis. Journal of the American Society for
Nephrology. 2010;21:1103–1114.
Svensson SL, Pasupuleti M, Walse B, Malmsten M, Mörgelin M, Sjögren C, Olin AI, Collin M,
Schmidtchen A, Palmer RH, and Egesten A. Midkine and pleiotrophin have bactericidal properties:
preserved antibacterial activity in a family of heparin-binding growth factors during evolution. Journal of
Biological Chemistry. 2010;285:16105–16115.
Yang R, Otten MA, Hellmark T, Collin M, Björck L, Zhao M-H, et al. Successful treatment of
experimental glomerulonephritis with IdeS and EndoS, IgG-degrading streptococcal enzymes.
Curriculum Vitae
Publications
Mattias Collin
May 2015
Nephrology Dialysis and Transplantation. 2010;25:2479–2486.
20. Daniel A, Euler CW, Collin M, Chahales P, Gorelick KJ, Fischetti VA. Synergism between a novel
chimeric lysin and oxacillin protects against infection by methicillin-resistant Staphylococcus aureus.
AAC. 2010;54:1603–1612.
21. Allhorn M, Briceño JG, Baudino L, Lood C, Olsson ML, Izui S, Collin M. The IgG-specific
endoglycosidase EndoS inhibits both cellular and complement-mediated autoimmune hemolysis. Blood.
2010;115:5080–5088.
22. Egesten A, Olin AI, Linge HM, Yadav M, Mörgelin M, Karlsson A, Collin M. SpeB of Streptococcus
pyogenes differentially modulates antibacterial and receptor activating properties of human chemokines.
PLoS ONE. 2009;4:e4769.
23. Holmberg A, Lood R, Mörgelin M, Söderquist B, Holst E, Collin M, Christensson B, Rasmussen M.
Biofilm formation by Propionibacterium acnes is a characteristic of invasive isolates. Clinical
Microbiology and Infection. 2009;15:787–795.
24. Karlsson C, Mörgelin M, Collin M, Lood R, Andersson M-L, Schmidtchen A, Björck L, Frick I-M. SufA
- a bacterial enzyme that cleaves fibrinogen and blocks fibrin network formation. Microbiology.
2009;155:238–248.
25. Allhorn M, Olsén A, Collin M. EndoS from Streptococcus pyogenes is hydrolyzed by the cysteine
proteinase SpeB and requires glutamic acid 235 and tryptophans for IgG glycan-hydrolyzing activity.
BMC Microbiology. 2008;8:3.
26. Albert H, Collin M, Dudziak D, Ravetch JV, Nimmerjahn F. In vivo enzymatic modulation of IgG
glycosylation inhibits autoimmune disease in an IgG subclass-dependent manner. Proceedings of the
National Academy of Science USA. 2008;105:15005–15009.
27. Collin M, Shannon O, Björck L. IgG glycan hydrolysis by a bacterial enzyme as a therapy against
autoimmune conditions. Proceedings of the National Academy of Science USA. 2008;105:4265–4270.
28. Linge HM, Collin M, Giwercman A, Malm J, Bjartell A, Egesten A. The antibacterial chemokine
MIG/CXCL9 is constitutively expressed in epithelial cells of the male urogenital tract and is present in
seminal plasma. Journal of Interferon and Cytokine Research. 2008;28:191–196.
29. Schmitz JE, Daniel A, Collin M, Schuch R, Fischetti VA. Rapid DNA library construction for functional
genomic and metagenomic screening. Applied and Environmental Microbiology. 2008;74:1649–1652.
30. Allhorn M, Olin AI, Nimmerjahn F, Collin M. Human IgG/Fc gamma R interactions are modulated by
streptococcal IgG glycan hydrolysis. PLoS ONE. 2008;3:e1413.
31. Collin M, Linge HM, Bjartell A, Giwercman A, Malm J, Egesten A. Constitutive expression of the
antibacterial CXC chemokine GCP-2/CXCL6 by epithelial cells of the male reproductive tract. Journal of
Reproductive Immunology. 2008;79:37–43.
32. Lood R, Mörgelin M, Holmberg A, Rasmussen M, Collin M. Inducible Siphoviruses in superficial and
deep tissue isolates of Propionibacterium acnes. BMC Microbiology. 2008;8:139.
33. Linge HM, Collin M, Nordenfelt P, Mörgelin M, Malmsten M, Egesten A. The human CXC chemokine
granulocyte chemotactic protein 2 (GCP-2)/CXCL6 possesses membrane-disrupting properties and is
antibacterial. Antimicrobial Agents and Chemotherapy. 2008 ;52:2599–2607.
34. Nandakumar KS, Collin M, Olsén A, Nimmerjahn F, Blom AM, Ravetch JV, Holmdahl R.
Endoglycosidase treatment abrogates IgG arthritogenicity: importance of IgG glycosylation in arthritis.
European Journal of Immunology. 2007;37:2973–2982.
35. Eliasson M, Frick I-M, Collin M, Sørensen OE, Björck L, Egesten A. M1 protein of Streptococcus
pyogenes increases production of the antibacterial CXC chemokine MIG/CXCL9 in pharyngeal epithelial
cells. Microbial Pathogenesis. 2007;43:224–233.
36. Karlsson C, Andersson M-L, Collin M, Schmidtchen A, Björck L, Frick I-M. SufA – a novel subtilisinlike serine proteinase of Finegoldia magna. Microbiology. 2007;153:4208–4218.
37. Collin M, Fischetti VA. A novel secreted endoglycosidase from Enterococcus faecalis with activity on
human immunoglobulin G and ribonuclease B. Journal of Biological Chemistry. 2004;279:22558–22570.
38. Åkesson P, Rasmussen M, Mascini E, Pawel-Rammingen von U, Janulczyk R, Collin M, et al. Low
antibody levels against cell wall-attached proteins of Streptococcus pyogenes predispose for severe
invasive disease. Journal of Infectious Diseases. 2004;189:797–804.
39. Collin M, Svensson MD, Sjöholm AG, Jensenius JC, Sjöbring U, Olsén A. EndoS and SpeB from
Streptococcus pyogenes inhibit immunoglobulin-mediated opsonophagocytosis. Infection and Immunity.
2002;70:6646–6651.
Curriculum Vitae
Publications
Mattias Collin
May 2015
40. Collin M, Olsén A. Effect of SpeB and EndoS from Streptococcus pyogenes on human immunoglobulins.
Infection and Immunity. 2001;69:7187–7189.
41. Collin M, Olsén A. EndoS, a novel secreted protein from Streptococcus pyogenes with endoglycosidase
activity on human IgG. EMBO Journal. 2001;20:3046–3055.
42. Collin M, Olsén A. Identification of conditionally expressed genes in Streptococcus pyogenes using
RNA fingerprinting. FEMS Microbiology Letters. 2001;196:123–127.
43. Collin M, Olsén A. Generation of a mature streptococcal cysteine proteinase is dependent on cell wallanchored M1 protein. Molecular Microbiology. 2000;36:1306–1318.
44. Kihlberg BM, Collin M, Olsén A, Björck L. Protein H, an antiphagocytic surface protein in
Streptococcus pyogenes. Infection and Immunity. 1999;67:1708–1714.
45. Herwald H, Collin M, Müller-Esterl W, Björck L. Streptococcal cysteine proteinase releases kinins: a
novel virulence mechanism. Journal of Experimental Medicine. 1996;184:665–673.
Review articles
1. Collin M, Olsén A. Extracellular enzymes with immunomodulating activities: variations on a theme in
Streptococcus pyogenes. Infection and Immunity. 2003;71:2983–2992.
2. Allhorn M, Collin M. Sugar-free antibodies--the bacterial solution to autoimmunity? Annals of the New
York Academy of Sciences. 2009;1173:664–669.
3. Garbe J, Collin M. 2011. Bacterial hydrolysis of host glycoproteins - powerful protein modification and
efficient nutrient acquisition. Journal of Innate Immunity. 2011; 4: 121-131.
4. Nelson DC, Garbe J, Collin M. Cysteine proteinase SpeB from Streptococcus pyogenes – a potent
modifier of immunologically important host and bacterial proteins. Biological Chemistry. 2011; 392:
1077-88.
5. Mattias Collin. EndoS, a “drug from a bug” as a novel treatment for autoimmunity of the blood ISBT
Science Series (affiliated with Vox Sanguinis). 2012; 7: 142-145
6. Collin M, Ehlers M: The carbohydrate switch between pathogenic and immunosuppressive antigenspecific antibodies. Experimental Dermatology 2013; 22: 511-514.
7. Sjögren J, Collin, M. Bacterial glycosidases in pathogenesis and glycoengineering. Future Microbiology.
2014; 9 (9): 1039-1051
Books edited
Collin, M., and Schuch, R. (eds). Bacterial Sensing and Signaling. Basel: Karger. 2009: 1-230.
Book chapters
Collin M, Kilian M: Bacterial Modulation of Fc Effector Functions. In Antibody FC: Linking Adaptive and
Innate Immunity. Edited by Ackerman ME, Nimmerjahn F, Elsevier. 2013.
Popular Science
1. Collin M. MATTIAS COLLIN, Årets Yngrepristagare. SLS aktuellt. 2009 Sep. 14;(3):1–26. [Swedish]
2.
Mattias Collin (2011) Bacteria can help us cure autoimmune disease. El Paìs, Dec 16.
3.
Mattias Collin (2011) Bacteria can help us cure autoimmune disease. Irish Times, Dec 11.
4.
Mattias Collin (2012) Vorbildhafte Krankheitserreger. Frankfurter Allgemeine, Jan 17.